InvestorsHub Logo
Followers 18
Posts 1458
Boards Moderated 0
Alias Born 11/01/2018

Re: bb8675309 post# 306287

Thursday, 04/08/2021 10:05:00 PM

Thursday, April 08, 2021 10:05:00 PM

Post# of 461947
Steady_T - It was last quarters earnings call 2/11/21

This is what I thought was our meeting on June 7th. I work long hours.

Christopher Missling -- President and Chief Executive Officer

Obviously, I cannot predict what will happen on June 7th when the meeting from the FDA will take place to decide about Adu. But I would say that if it turns out positive, and that is a scenario you referred to, it would actually mean that the FDA would agree that one robust clinical study would be sufficient to approve a drug in Alzheimer's disease. And since we are running now a robust Phase 2b/3 study as well, this could be a positive for us in that regard. If the decision on the 7th of June is more negative in outcome, then it would still not, I believe will not in way or shape impaired because we are basically, by that time, advanced with our study and there's also ability for supportive data from the Phase 2a with our Phase 2b/3 study.

So we just put our heads down and move ahead, but I would think that it's possible that there will be positive resonance if the study would be approved -- the other study would be approved mid of the year.


https://www.fool.com/earnings/call-transcripts/2021/02/11/anavex-life-sciences-avxl-q1-2021-earnings-call-tr/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News